MET@Learning APAC Live Webinar:
Focus on METex14 in Advanced NSCLC
Release date: 21-10-2024
Expiration date: 21-10-2025
In recent years, precision medicine for lung cancer has evolved rapidly. The use of advanced testing technology for genomic profiling in tissue and plasma (e.g. next generation sequencing, NGS) has led to the identification of new actionable molecular drivers, including MET exon 14 (METex14) skipping mutations and other alterations. Several new targeted therapies have recently entered clinical practice based on clinically meaningful efficacy and a favorable safety profile for METex14 skipping mutations. However, despite these advances, the molecular testing in clinical practice, especially for uncommon alterations, remains suboptimal and available methods are not used appropriately. Consequently, patients may not receive optimal treatment regimens. In addition, practicing physicians often don’t feel confident in interpreting NGS results, treatment selection/sequencing, and managing adverse events (AEs) to targeted therapy.
The webinar will include a combination of presentations focusing on the importance of broad molecular profiling to avoid missing detection of actionable biomarkers, and how to use new targeted treatment options to optimize care of patients in advanced NSCLC with METex14 skipping mutations. Additionally, the experts will also present the clinical cases on how to treat patients with different scenarios in their clinical practice, which will help the clinicians to get more insights.
This English program is available with subtitles in Chinese.
Faculty
Baohui Han, MD, PhD | Co-chair
Shanghai Chest Hospital
Shanghai Jiaotong University
Baohui Han, MD, PhD is a Professor in the Department of Respiratory Medicine at Shanghai Chest Hospital. He also serves as Vice-president and Chief of Pulmonary Department. Dr. Han has been recognized as a leading talent in Shanghai City and has received the State Council special allowance for his expertise. Additionally, he holds the position of Chief of Clinical Trails Centre at Shanghai Chest Hospital in China.
His research interests focus on lung cancer biological immune targeted therapy and clinical trials on new anti-tumor drugs. As a Principal Investigator (PI) or Co-PI, Dr. Han has actively participated in numerous international multi-center clinical trials including IPASS, EAP, INTEREST, INFORM, S012, MOK-806, IGNITE, LEAP007, ALTER 0303, BEYONG, JO41492 and other 57 clinical trials. Recent evaluations have shown that Dr. Han's enrollment quantity and quality ranked highest among domestic researchers involved in influential international multi-center IPASS clinical research. In fact, Dr. Han led a single center with the largest number of enrolled patients worldwide for clinical research purposes.
Throughout his career, he has received multiple awards including "The Eighth Chinese Respiratory Physicians Award" in 2013,"China Medical Science and Technology Award" in 2014, and "Shanghai Medical Science Award" on several occasions. Furthermore, Dr. Han is a committee member of numerous associations and societies. He is an executive member of CSCO, the chairman of Tumor Branch Chinese Medical Biological Immunology Society, vice-president of Shanghai Cancer Society, and vice-chairman of Shanghai Medical Association for Tumor Target Molecule.
Myung-Ju Ahn, MD, PhD | Co-chair
Samsung Medical Center
Sungkyunkwan University School of Medicine
Seoul, South Korea
Myung-Ju Ahn, MD, PhD is a Professor of Hemato-Oncology at the Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, South Korea. Her research interests include the development of predictive and prognostic markers for personalized lung cancer therapy. She has recently focused on early clinical trials for the development of drug discovery and repositioning of targeted drugs and the development of a non-small cell lung cancer (NSCLC) genome atlas. Professor Ahn received her medical and doctoral degrees from Hanyang University College of Medicine, Seoul, and completed her residency training at Hanyang University Hospital. She has held numerous research fellowships, including a postdoctoral research fellowship at the Memorial Sloan-Kettering Cancer Center, New York, US, and has authored over 300 cancer research publications.
Professor Ahn is a member of numerous research associations and societies, including the IASLC (International Association for the Study of Lung Cancer), AACR (American Association of Clinical Research), and ASCO (American Society of Clinical Oncology), and is currently Chief of the Executive Committee and Chairperson of the Lung Cancer Disease Committee of the KCSG (Korean Cancer Study Group) and director of Korean Association for Lung Cancer Association (KALC). She was President of the Korean Society of Medical Oncology (KSMO) and has also been Chair of the multidisciplinary Immuno-oncology Study Group (2017–2018). She is a board member for the Korea Cancer Society (KCA) and KSMO, and is on the editorial board of Journal of Thoracic Oncology. Professor Ahn’s accolades for her dedication to cancer research include: Best Researcher Award, Korean Medical Women Association (2003); Best Researcher Award, Korean Society of Medical Oncology (2015); Boryoung Scientific Award, Korean Cancer Research Foundation (2018); Wunsch Medical Award, Korean Academy of Medical Science (2020); Excellent Researcher Award, Minister of Health and Welfare (2021); Adi. F. Gadzar Merit Award from IASLC (2023), and Highly Cited Researcher, Clavirate Analytics (2019, 2020, 2021, 2022, 2023).
Helena A. Yu, MD
Memorial Sloan Kettering Cancer Center
New York, USA
Helena A. Yu, MD is a Thoracic Medical Oncologist at the Memorial Sloan Kettering Cancer Center, New York, USA. She is an Associate Professor and Research Director for the Thoracic Oncology Service.
Dr Yu has a special interest in the development of novel targeted therapies for the treatment of lung cancer. She has co-authored more than 100 peer-reviewed publications, of which several focus on EGFR mutations in non-small cell lung cancer. Dr Yu oversees the clinical research program for patients with EGFR-mutant lung cancer at the Memorial Sloan Kettering Cancer Center, and has been principal investigator on more than 20 studies.
Her Board Certifications include Internal Medicine and Medical Oncology and completed her residency in internal medicine at the Hospital of the University of Pennsylvania. Dr Yu received her MD from the University of Michigan Medical School and is dedicated to creating comprehensive treatment plans tailored to patient needs and goals.
In 2021, Dr Yu received an NCI R01 as well as the EGFR Resisters/LUNGevity Lung Cancer Research award for her work on the molecular characterization of lineage plasticity.
Tang Hao, MD, PhD
Shanghai Changzheng Hospital
Shanghai, China
Tang Hao, MD, PhD is currently serving as the Chief of the Department of Respiratory and Critical Care Medicine at Shanghai Changzheng Hospital. He also holds positions as an Associate Professor and Deputy Chief Physician. Dr. Tang has dedicated his career to medical practice, teaching, research, and healthcare service in the specialized field of respiratory and critical care. His expertise lies in the diagnosis and treatment of chronic airway diseases, personalized therapies for lung cancer patients, management of challenging and critical respiratory conditions, as well as respiratory intervention therapy. Dr. Tang actively contributes to various professional organizations including being a Youth Committee Member of the Respiratory Physicians Branch under Chinese Medical Association. Additionally, he serves as Vice Group Leader within the Asthma Study Group affiliated with Shanghai Society for Respiratory Diseases Branch while also holding a position on the Committee Member roster for Shanghai Physicians Association's Respiratory Physicians Branch. Recognized for his outstanding contributions to academia in Shanghai City Health System's "New Excellent Youth" program; Dr. Tang has been honored with titles such as Outstanding Academic Leader in Shanghai City along with being designated a Shuguang Scholar and Pujiang Talent Program Recipient. Dr. Tang has successfully led 4 projects funded by National Natural Science Foundation alongside 6 provincial-level research projects throughout his career thus far. Furthermore, he boasts an impressive publication record consisting of over 30 SCI papers published in internationally renowned journals like European Respiratory Journal and American Journal of Respiratory & Critical Care Medicine.
Nick Pavlakis, MBBS, MMEd (Clin Epi), PhD
Royal North Shore Hospital
The University of Sydney
Sydney, Australia
Nick Pavlakis, MBBS, MMEd (Clin Epi), PhD is a Senior Medical Oncologist at the Royal North Shore Hospital, North Shore Private Hospital, and Northern Cancer Institute (GenesisCare) in Sydney, Australia, and Professor of Medicine at the Northern Clinical School, University of Sydney. He is also Co-Chair of the Bill Walsh Translational Cancer Research Laboratory at the Royal North Shore Hospital. He has more than 20 years’ experience in the oncology field, including clinical and translational research.
Professor Pavlakis is trained in anti-angiogenic drug development, and he has an interest in new drug development and evaluation of drug resistance in lung cancer, mesothelioma, and GI malignancies, particularly NETs (Neuroendocrine Tumors). He is the Board Chair of the Thoracic Oncology Group of Australia (TOGA). He is study co-chair of several national and international co-operative group studies, including the TOGA ASPiRATION trial evaluating upfront comprehensive genomic profiling in newly diagnosed non-small cell lung cancer (NSCLC). He is IASLC (International Association for the Study of Lung Cancer) CME (Continuing Medical Education) and Education Committee co-Chair and was on faculty for the 2023 World Conference on Lung Cancer (WCLC).
Jii Bum (Joy) Lee, MD, PhD
Yonsei Cancer Center
Seoul, South Korea
Jii Bum (Joy) Lee, MD, PhD is a clinical professor at Yonsei Cancer Center, Severance Hospital in the Division of Medical Oncology, Department of Internal Medicine in Seoul, South Korea. She specializes in medical oncology and focuses on lung cancer and head and neck cancer. Her research interests include treatment refractory non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations, as well as immunotherapy for NSCLC without actionable molecular biomarkers.
Minjiang Chen, MD, PhD
Peking Union Medical College Hospital
Beijing, China
Minjiang Chen, MD, PhD serves as the Deputy Chief Physician in the Department of Respiratory and Critical Care Medicine at Peking Union Medical College Hospital. Dr. Chen specializes in personalized treatment for respiratory diseases and respiratory system tumors. She has previously worked and studied as a visiting scholar at the Chest Tumor Center and Helen Diller Family Comprehensive Cancer Center (HDFCCC) at the University of California, San Francisco (UCSF). She has led research projects funded by the National Natural Science Foundation of China and Beijing Cancer Prevention and Treatment Research Association, as well as participated in various research projects supported by the Ministry of Science and Technology of China, Beijing Natural Science Foundation, among others. As a Key-Sub-Investigator member, she has been involved in over 40 international/domestic multi-center clinical studies and published more than 20 SCI papers. Additionally, she has contributed to three books as an author or co-author. Dr. Chen holds positions on several professional committees including: Member-in-Charge (preparatory) of Pleural Diseases Group under Chinese Medical Association Respiratory Disease Branch; Committee Member of Interventional Oncology Professional Committee under Chinese Anti-Cancer Association; Youth Committee Member of China Lung Cancer Prevention & Control Alliance; Youth Committee Member of China Pharmaceutical Education Association Lung Cancer Specialized Commission; Beijing Society for Oncology Lung Cancer Specialized Commission; Endoscopy Sub-Committee under Beijing Society for Oncology Prevention & Treatment Research Association; Adverse Drug Reaction Sub-Committee under Beijing Society for Oncology Prevention & Treatment Research Association.
- Optimizing biomarker detection for METex14 skipping in advanced NSCLC | Helena A Yu, MD
- Evolving treatment options for METex14 skipping: Where are we now? | Hao Tang, MD, PhD
- Panel Discussion: Optimal strategies for biomarker testing and treatment selection in METex14 skipping | Moderator: Myung-Ju Ahn, MD, PhD
- How I treat 1L patients with METex14 skipping | Jii Bum (Joy) Lee, MD, PhD
- How I treat perioperative patients with METex14 skipping | Minjiang Chen, MD, PhD
- Moving forward with MET inhibitors: Embarking on an expedition for the future | Nick Pavlakis, MBBS, MMEd (Clin Epi), PhD
- Panel Discussion: Treatment decision-making in clinical practice and the evolving landscape | Moderator: Baohui Han, MD, PhD
The proposed educational activity is designed specifically for medical oncologists, pulmonologists, pathologists, oncology fellows, and other healthcare professionals involved in the management of patients with lung cancer in the APAC region and China.
Upon completion of this educational activity, participants should be able to:
- Assess broad molecular genomic profiling techniques, such as NGS (in tissue and plasma) to optimize detection approaches for METex14 skipping mutations
- Highlight the importance of early detection of METex14 skipping mutations and subsequent frontline use of targeted therapy
- Evaluate optimal treatment strategies for selective MET inhibitors in first-line (1L) and later-line patients with METex14 skipping
- Optimize AE management for MET inhibitors to maximize clinical outcomes
This activity is provided by ACE Oncology.
This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.
The Faculty of Pharmaceutical Medicine has approved this event for CPD and allocated it 1.5 continuing professional development credits (CPD).
This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve the competence and performance of learners in order to improve patient care. There is no fee for this activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Baohui Han has no financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Myung-Ju Ahn has served as an advisor or consultant for Alpha-pharmaceuticals, Amgen, AstraZeneca, Arcus, Daiichi-Sankyo, Genexin, Gilead, Merck, MSD, Pfizer, Roche, Voronoi, and Yuhan. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Helena A Yu has has served as an advisor or consultant for AbbVie, Amgen, AstraZeneca, Daiichi-Sankyo, Taiho, and Takeda. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Hao Tang has no financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Jii Bum (Joy) Lee has no financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Minjiang Chen has no financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Nick Pavlakis has served as an advisor or consultant for Amgen, Astra Zeneca, Beigene, BMS, Gilead, MSD, Merck, Pfizer, Takeda, Roche, and Zymeworks. He has received honorarium as speaker from Bayer, Illumina, MSD, Merck, Pfizer, Roche, and Takeda. Dr. Pavlakis has also received grants for clinical research from Bayer, Pfizer, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of ACE Oncology have disclosed no relevant financial relationships.
ACE Oncology requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.